Background-Inherited arrhythmia syndromes are responsible for a significant portion of autopsy-negative sudden unexpected death (SUD) cases, but molecular autopsy used to identify potentially causal variants is not routinely included in SUD investigations. We collaborated with a medical examiner's office to assist in finding a diagnosis for their autopsynegative child SUD cases. Methods and Results-191 child SUD cases (<5 years of age) were selected for analyses. Our next generation sequencing panel incorporated 38 inherited arrhythmia syndrome candidate genes and another 33 genes not previously investigated for variants that may underlie SUDY pathophysiology. Overall, we identified 11 potentially causal disease-associated variants in 12 cases, for an overall yield of 6.3%. We also identified 31 variants of uncertain significance in 36 cases and 16 novel variants predicted to be pathogenic in silico in 15 cases. The disease-associated variants were reported to the medical examiner to notify surviving relatives and recommend clinical assessment. Conclusions-We have identified variants that may assist in the diagnosis of at least 6.3% of autopsy-negative child SUD cases and reduce risk of future SUD in surviving relatives. We recommend a cautious approach to variant interpretation. We also suggest inclusion of cardiomyopathy genes as well as other candidate SUD genes in molecular autopsy analyses.
S
udden unexpected death (SUD) of a child is devastating for parents and the community at large. It is particularly stressful to caregivers when no cause is identified after a thorough death investigation that includes a careful autopsy and ancillary examinations including toxicology, microbiology, and other analyses. It has long been postulated that ventricular arrhythmias are often the main suspect underlying autopsy-negative SUD.
See Clinical Perspective
Recently, molecular genetic testing (ie, molecular autopsy) has provided clues to the cause of death in some of the autopsy-negative SUD in the young (SUDY), including infants and young children. Molecular autopsy and clinical evaluation of surviving relatives demonstrate that at least one third of SUDY cases are because of lethal arrhythmia attributed to inherited arrhythmia syndromes (IAS). [1] [2] [3] [4] [5] These include both primary electric disorders of the heart-ion channelopathies (eg, long-QT syndrome) 6 and certain cardiomyopathies, for example, familial hypertrophic cardiomyopathy (FHC) that may play a role in autopsy-negative SUDY, 7 as these disorders may have a concealed arrhythmogenic phase before manifestation of structural defects. 8 High-throughput next-generation sequencing (NGS) technology offers the opportunity to identify potentially pathogenic variants at ever-decreasing cost. The list of candidate genes for IAS has also expanded dramatically because targeted and wholeexome sequencing (WES) approaches have provided opportunities to explore new genes and other genomic regions of interest. In Canada and elsewhere, physicians are referring their living patients, but death investigators have not routinely used genetic testing to assist in the diagnosis of SUDY, despite international guidelines and protocols in existence since 2008. [9] [10] [11] In this population-based study, in conjunction with the Manitoba medical examiner's office, we investigated 191 Investigating Child SUD autopsy-negative child SUD cases. With this large cohort, we also wanted to explore other potential candidate genes for IAS and SUDY. We hypothesized that genetic variants that disrupt critical signaling pathways (for example, adrenergic signaling during physical or emotional exertion) and calcium homeostasis may play a role in creating the substrate for triggering arrhythmias. Furthermore, genes that are uniquely or differentially expressed in infants and young children have not yet been examined for causality in SUDY.
Our main objective in this study was to design and validate an NGS panel and workflow using IAS and SUDY candidate genes and genes not previously or routinely investigated. Our second objective was to determine whether our results could inform the use of molecular autopsy in all cases of autopsy-negative SUDY.
Methods

Selection of Genes for the Sequencing Panel
A total of 71 genes were selected for the sequencing panel. In addition to 38 IAS-associated genes, including long-QT syndrome, short-QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, FHC, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy (Table 1) , we also included 33 genes that have not been previously or routinely investigated in IAS and SUDY cases (Table 2) . Some genes are associated with calcium homeostasis and its role in cardiac excitation and contractility; for example, SLC8A1 encoding NCX1, the sodium-calcium exchanger (member 1). Our previous research suggests that NCX1 has a more important physiological role in neonatal hearts than in adult heart. 12 We selected other genes that have high expression levels throughout infancy; for example, TNNI1 that encodes the dominantly expressed troponin I paralog in fetal and infant hearts. 13 Table I in the Data Supplement includes justification for including the additional 33 genes.
Selection of SUD Cases and DNA Preparation
Permission to conduct the analysis on child SUD cases was given by the Chief Medical Examiner of Manitoba, and approval was obtained from the ethics review boards of Simon Fraser University, the University of Manitoba, the Winnipeg Health Sciences Center's Pediatric Research Review Committee, and the Pathology Access to Tissue Committee.
Cases of child SUD (age ≤5 years at time of death) from 1994 to 2013 were reviewed and included in the study if they met the study criteria of no cause of death after autopsy and investigation of the circumstances and scene. The autopsies were rigorously performed following in-house protocols for child deaths occurring up to 5 years of age adapted from the Canadian Association of Pathologists Guidelines for Medicolegal Autopsies in Canada (https://www.capacp.org/guidelines.php). The practices include a full toxicology screen, a full skeletal x-ray survey, bacterial/viral/fungal cultures, metabolic disorder screen, and neuropathology consultation. Children with identifiable heart disorders (eg, tetralogy of Fallot, valvular heart disease, etc) and other potentially life-threatening medical conditions were excluded. Post-mortem heart, psoas muscle, or liver tissue retained from autopsy and stored at −70°C was deidentified and sent to our laboratory at Simon Fraser University. Genomic DNA was extracted following the manufacturer's protocol using a Qiacube robot (Qiagen) and quantified using a Qubit fluorometer (Thermo Fisher Scientific). Genomic DNA quality was analyzed using 1% agarose gel electrophoresis. A 100 ng of each DNA sample was sheared to 300 bp lengths using a Covaris M220 ultrasonicator (Covaris) and quality checked using an Agilent 2100 Bioanalyzer (Agilent Technologies). To be consistent with other sequencing reports in the literature, we divided our child population into 2 cohorts: a sudden unexpected death in infancy (SUDI) division for cases under 12 months and a sudden unexpected death in childhood (SUDC) division for cases aged 1 to 5 years of age at time of death.
Preparation for Sequencing
For each sample, 50 ng of DNA was used for library construction using the KAPA LTP Library Preparation kit following a modified protocol (Data Supplement). The final library DNA concentration was measured using a Qubit fluorometer and quality checked using an Agilent 2100 Bioanalyzer on a random, small number of samples.
Exonic targeted enrichment of the genes of interest (Tables 1 and  2 ) was achieved with custom-ordered biotinylated oligonucleotide probes using a modified IDT XGen Lockdown capture protocol (Data Supplement). Post-capture library yields were evaluated using a Qubit fluorometer, and enrichment was evaluated through a quantitative polymerase chain reaction experiment relying on the amplification of 1 ontarget locus versus 1 off-target locus. The captures were sequenced on an Illumina MiSeq NGS platform with 150 bp paired end reads.
Data Analysis, Variant Detection, and Validation
After sequencing, the MiSeq-generated FASTQ files were aligned to a reference sequence representing the 71 genes of interest derived from the human GRCh37.p13 (hg19/Ensembl75) genome sequence using Geneious v8.1.7 software.
14 Paralogs and pseudogenes for these genes (where present in the reference genome) and highly similar loci were also included in this reference to avoid erroneous read mapping. The aligned reads were processed and analyzed to identify variants (both single nucleotide variants and insertions/deletions) using Geneious software and annotated using the Oncotator online application. 15 Through the dbNSFP 16 Oncotator data source, variants were annotated using several functional prediction and conservation score algorithms (PolyPhen-2, SIFT, MutationTaster, Mutation Assessor, FATHMM, LRT, SiPhy, GERP++, and PhyloP) and used to classify variants most likely to affect a protein's function. Insertions/deletions were further analyzed using the PROVEAN online software prediction tool. 17 Sequence variants were filtered using a minor allele frequency threshold of ≤0.1%. Variants with allele frequencies above our threshold were retained in a separate database to be analyzed for clinical significance. Select variants with poor coverage (<30-fold) or with poor read quality scores were validated using deep amplicon sequencing. 18 All purportedly rare variants, including potentially novel variants, were quality checked and frequency filtered by searching variant databases, including The Single Nucleotide Polymorphism database (dbSNP) (http://www.ncbi.nlm.nih.gov/SNP/) and the Exome Aggregation Consortium (ExAC) database (http://exac. broadinstitute.org/) and, more recently, the Genome Aggregation Database (http://gnomad.broadinstitute.org/). The above databases and several others, including ClinVar, the Human Genetics Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php), and Online Mendelian Inheritance of Man, were extensively searched to assist in determining clinical relevance. Variants were categorized using the 5-tier classification system recommended by the American College of Medical Genetics (ACMG) and in ClinVar: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. 19 Any variants implicated in disease were promoted as potentially causal. These variants underwent a further filtering strategy using Ware's online maximum tolerated allele frequency calculator (http://cardiodb.org/allelefrequencyapp/) to calculate the maximum tolerated allele counts of found variants within the ExAC and gnomAD reference data sets. 20 Novel variants predicted to prematurely truncate the protein either by introducing a stop codon or frame shift, as well as those with high prediction software scores (ie, predicted to functionally impact the protein) were considered the best candidates and prioritized for functional analyses by ourselves and our collaborators. These findings will be reported in future publications. Selected variants of interest (for functional analysis) were validated using digital drop polymerase chain reaction assay.
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Statistical Analysis
The data were summarized using descriptive statistics (means, percentages).
Results
Cohort and Sample Acquisition
A total of 191 child SUD cases were selected for our cohort, of which 122 (64%) were males. The age at time of death ranged from 1 day up to 4.5 years (54 months). There were 182 cases in the SUDI cohort, with an average age of 3.2 (±0.2) months, of which 62.6% were males. There were 9 cases in the SUDC cohort with an average age of 19.6 (±4.4) months, of which all but 1 were male (88.9%). Deidentified autopsy reports were only provided for cases with disease-associated variants or novel variants predicted to be pathogenic or likely pathogenic; ARVC indicates arrythmogenic right ventricular cardiomyopathy; BrSX, Brugada syndrome type X; CPVTX, catecholaminergic polymorphic ventricular tachycardia type X; DCM, dilated cardiomyopathy; FHC, familial hypertrophic cardiomyopathy; IAS, inherited arrhythmia syndrome; LQTX, long-QT syndrome type X; SQTX, short-QT syndrome type X; and SSSX, Sick sinus syndrome type X. Investigating Child SUD thus, no correlations could be made between genotype-positive and -negative cases. Furthermore, the autopsy reports did not contain detailed background information, such as ancestry, medical or family history, or activity at time of death which may have assisted in the interpretation of variant clinical relevance.
All 191 tissue samples yielded ample amounts of highquality DNA despite some being in storage for >20 years. The average DNA concentrations were 192.53 (±2.79) ng/mg of heart, 78.55 (± 24.63) ng/mg of psoas muscle, and 387.85 (±140.14) ng/mg of liver tissue. Minimal to no degradation of DNA was observed using gel electrophoresis.
Sequencing Results
After the reads were processed, 346 total rare variants were found in 157 cases. Careful database searches (as discussed in Methods) led to the discovery of 11 potentially causal variants in 12 cases for an overall yield of 6.3%. Of these 23 variants, 6 were classified as pathogenic or likely pathogenic using the criteria outlined in the ACMG guidelines 19 and therefore were considered to be clinically relevant ( Table 3 ). The other 6 variants, although associated with a disease phenotype in previous reports, were identified as having "conflicting interpretations of pathogenicity" in ClinVar and weak evidence for pathogenicity, via biophysical analyses or familial segregation (Table  4) . One additional variant, MYH7 p.A1763T, found in 4 cases (3 in the SUDI cohort and 1 in the SUDC cohort), was listed in ClinVar as having conflicting interpretations of pathogenicity, although its most recent classification was likely pathogenic (1 likely pathogenic and 4 uncertain significance classifications as of May 30, 2017) . Its allele count in the gnomAD database (19/277 242 alleles overall and 14/126 724 alleles in the nonFinn European population) was found to exceed the maximum tolerated allele counts of 17/277 242 and 9/126 724 using the Ware online allele frequency calculator as described above. Table II in the Data Supplement provides a list of recently downgraded variants previously reported as pathogenic or likely pathogenic that we discovered in our cohorts.
SUDI Cohort
There were 149 SUDI cases overall with 95 rare variants identified. There were 6 cases harboring 6 potentially pathogenic variants (Table 3 ) and 5 cases with 6 variants identified with conflicting interpretations of pathogenicity in ClinVar (Table 4 ). In addition, we found 27 VUS in 29 cases, and 14 novel variants predicted to be pathogenic in silico in 13 cases in this cohort.
SUDC Cohort
Of the 9 cases in this cohort, one was identified with potentially causal variants: a 54-month-old female who was found deceased in a second-story bedroom following a meal. Two pathogenic variants in 2 different IAS-associated genes, CAC-NA1C p.G402S and PKP2 p.W538*, were identified (Table 3) . Pathogenic variants in the CACNA1c gene cause dysfunction in the cardiac L-type calcium channel (Cav1.2) likely causing Timothy syndrome (LQT8) with abnormalities, including cardiac malformations, severe life-threatening arrhythmias, syndactyly, and autism. The CACNA1C p.G402S variant, however, is associated with an atypical Timothy syndrome phenotype in which patients experience severe arrhythmias, but without the other physical manifestations. 22 Hence, it would be difficult to diagnose postmortem without molecular autopsy. In this child cohort, we also identified 2 novel variants in 2 cases, and 5 VUS in 4 cases, including 1 case harboring MYH7 p.A1763T, as described above. We have begun investigating an intriguing variant, TNNI1 p.R37C, discovered in 9 cases of our SUDI cohort and in 1 case of our SUDC cohort. The TNNI1 gene encodes the neonatal form of troponin I that is predominantly expressed in infant hearts, and in this study, we show that the TNNI1 transcript is expressed >50-fold higher than that of TNNI3 in cardiomyocytes derived from human-induced pluripotent stem cells up to 155 days after differentiation (methodology described in the Data Supplement and data shown in Figure I in the Data Supplement). Consistent with this, all 10 children harboring this mutation died under 20 months of age and 7 under 4 months of age. Preliminary structural analyses demonstrate that this substitution effectively disrupts troponin I and troponin T interactions, reminiscent of that seen in FHC, making the R37C variant a viable subject for future functional characterization ( Figure II in the Data Supplement). More information on clinical relevance of a select number of variants of unknown significance (including TNNI1 p.R37C) will be reported separately after completion of ongoing functional analyses.
Despite several attempts to increase captures by refining protocols, some genes (eg, CAMK2D and CAMK2D) had low coverage. Therefore, heterozygous variants may have been missed in our cohort because of poor representation of a few genes in our captures. There were no rare pathogenic variants identified in 34 cases (17.8%) in the SUD cohort. Twenty of these cases were selected and subjected to WES to determine whether they have rare variants in any IAS-genes not included in our 71 gene panel and will be included in a future report.
Discussion
In this study, we report the finding of potential disease-causing variants in a large population of autopsy-negative child One drawback for conducting molecular autopsies is the lack of appropriate tissue retained at autopsy, as well as lack of policy and protocols. 23 In most jurisdictions, if tissue is retained, it is frequently formalin fixed and paraffin embedded, which limits the amount and quality of nucleic acids that can be extracted. All 191 samples in our cohort produced adequate amounts of good quality genomic DNA which exemplifies that fresh frozen postmortem tissue stored at −70°C is an ideal source of DNA for molecular autopsy.
The main objectives for this study were to determine whether disease-associated variants could be found in autopsynegative SUDI and SUDC cohorts and whether the incidence of variants will inform the use of molecular autopsy for future case investigations. We successfully identified 6 previously published disease-associated variants in 7 (3.7%) cases that are classified as pathogenic or likely pathogenic using the ACMG guidelines. We identified another 6 variants that have conflicting interpretations of pathogenicity (ie, pathogenic, likely pathogenic, and uncertain significance listed for each variant in ClinVar) in 5 cases (2.6%) for an overall yield of 6.3%. We have chosen not to include MYH7 p.A1763T on our list of potentially causal variants in Table 4 , although the most recent ClinVar submission shows this variant as likely pathogenic. The allele count for A1763T in the gnomAD data set is 19 out of 277 242 alleles overall and specifically 14 in 126 724 non-Finnish Europeans. The maximum tolerated allele count, using an expected allele frequency of 0.0004 and assuming 50% penetrance (as described in Whiffin et al 20 ) , is calculated to be 17 in 277 242 and 9 in 126 724, placing its potential pathogenicity in doubt.
Another objective for this study was to determine whether adding genes not previously investigated for IAS and SUDY to the sequencing panel would increase diagnostic yield. We did not identify any disease-associated variants using the 33 additional non-IAS genes. There were 34 cases in our cohort that did not have a potentially pathogenic variant identified using our targeted gene panel and have undergone WES to determine whether they have variants in other genes. Considering that there are now well >100 candidate genes for IAS, we anticipate finding variants that will increase our overall yield and help to inform which genes should be included to further refine our targeted sequencing approach. We will include these findings in a future report. Furthermore, we have begun investigations on TNNI1 p.R37C that demonstrate that the R37C mutation is a viable subject for future functional characterization at the molecular, cellular, and tissue levels, to substantiate its pathogenicity in infancy (Data Supplement). We also identified 9 novel variants predicted to be pathogenic in 7 genes not previously or routinely investigated for IAS and SUDY. In addition, 2 novel nonsense variants were found in the CAMK2G gene. These variants are predicted to prematurely truncate the protein and both variants were located closer to the 5′ than the 3′ terminus of the gene which is highly likely to impact protein function. These novel variants will undergo functional analysis to provide additional evidence for clinical relevance.
Preliminary evidence from our study suggests that the diagnostic yield may be increased by expanding the gene panel to incorporate other candidate genes. A recent study by Bagnall et al 24 supports this suggestion; genetic analysis of a large SUD cohort (113 cases aged 1 to 35 years) revealed a 9% diagnostic yield in the conventional molecular autopsy genes (4 genes: KCNQ1, KCNH2, SCN5A, and RYR2). Genetic analysis of an additional 55 cardiac genes increased the diagnostic yield to 27%. In addition, 62 cases in their cohort underwent genetic analysis of 72 epilepsy genes with the finding of 4 potentially causal variants for a yield of 6% in this subset. This finding suggests that undiagnosed heritable seizure disorders may be a potential cause underlying SUDY.
Our overall yield (6.3%) might be considered low compared with other similar studies due, in part, to our decision to exclude the VUS until they undergo functional analysis, and we have cosegregation data for any phenotypically positive surviving relatives.
To limit false-positive results, we followed the criteria recommended by the recent ACMG guidelines, which urges caution when using "absent from controls" and for relying on in silico algorithms for variant classification. We also checked for rare and common variants that may "rescue" the functional impact of purportedly pathogenic mutations. For example, the SNTA1 p.A257G has been previously reported to be associated with LQTS, but the common variant, SNTA1 p.P74L is thought to alleviate the pathogenicity. This may explain why the A257G variant has been discovered in control cohorts (and 3 SUDI cases) when they also harbor the P74L variant. 25 Both the SNTA1 p.A257G and the common p.P74L variant were found in two of our cases. Another common variant, SCN5A p.H558R, has also been reported as a genetic modulator that improves sodium channel activity in mutated channels by repairing abnormal channel gating kinetics and membrane trafficking. For example, 2 variants SCN5A p.V1951L and p.P2006A have both been previously reported as LQT3 candidates, but in the presence of the H558R variant, sodium channel function in vitro was similar to wild-type channel current. 26 We found SCN5A p.V1951L+H558R in 3 cases, and SCN5A p.P2006A+H558R in another case; however, given the above findings, their status in the ClinVar database (eg, likely benign for P2006A), and their relatively high allele frequencies in control populations, SCN5A p.V1951L and P2006A, are not considered pathogenic. Conversely, SCN5A p.H558R, in the presence of the common and likely benign A572D variant, showed moderate sodium channel dysfunction in vitro, suggesting some evidence of being a potential LQT3 candidate. 27 The interaction of common and rare variants speaks to the complexity of variant interpretation that requires careful scrutiny (including how much importance to place on in vitro functional analyses and how much functional impact is required in these analyses for clinical relevance).
Our comparatively low yield may also reflect that the majority of our subjects are infants (95% under 1 year of age). Hence, we have divided our population into 2 cohorts (SUDI and SUDC cohorts) and reported their findings separately in Table 3 . The yield in our SUDI cohort is 5.8%. The diagnostic yield in SUDI cases has traditionally been much lower than other age categories, in the range of 5% to 15% (review by Klaver et al 28 ). One recent NGS study using 100 ion channelopathy and cardiomyopathy genes had a much higher yield Investigating Child SUD of 34% in 47 SUDI cases. However, unlike our study, they included their novel variants in their overall yield. Their novel variant pathogenicity interpretations were based on conservation, computational prediction, and allele frequency and were not verified with family or functional studies. 7 Interestingly, similar to our findings, this study also found a number of cardiomyopathy-associated variants. Brion et al 29 investigated a large cohort of autopsy-negative SUDI for cardiomyopathyassociated variants and found that 4% harbored a pathogenic or likely pathogenic variant. We therefore suggest including cardiomyopathy-associated genes in SUDI screening panels. In 2014, Bagnall et al 30 sequenced 28 SUDY cases ranging in age from 1 to 40 years. Their diagnostic yield was 10% using the 4 conventional molecular autopsy genes, but using an additional 26 arrhythmia and 41 cardiomyopathy genes increased their overall yield to >30%. Recently, Nunn et al 31 investigated 59 autopsy-negative SUDY cases, (including pediatric SUD cases) using a panel of 135 ion channelopathy and cardiomyopathy genes and found several variants that were identified in our cohort, including LMNA p.R644C and 2 channelopathy-associated variants, CACNA1C p.G37R and KCNH2 p.P347S (discussed below). In another recent study, Anderson et al 32 used WES, focusing on 100 ion channelopathy and cardiomyopathy-associated genes, to investigate the genetic causes of exertion-related, autopsy-negative pediatric SUDY. Although the cohort was small (n=21), they uncovered a novel, potentially pathogenic ARVC variant, PKP2 p.N634fs. The heterogeneous nature of ARVC, plus its insidious disease progression that includes a concealed, arrhythmogenic phase 8 make it a disorder that we suggest should be screened in pediatric SUD cases. Similarly, DCM is another candidate disorder underlying SUDY cases as disease onset can occur in early infancy and without presentation in the parents, because of sporadic, de novo mutations or poor penetrance, and some patients show a higher propensity for arrhythmic events without overt disease phenotype ("arrhythmogenic DCM"). 33 Some FHC patients, especially younger individuals, may present with minimal or negligent hypertrophy and high risk for SUD. 34 These studies suggest that cardiomyopathies do play a role in infant and child SUD cases.
WES has facilitated development of large populationbased databases which in turn have revealed higher than expected frequencies of disease-associated variants in reference populations leading to reassessment of variant pathogenicity. Furthermore, throughout the duration of this study, reference data sets have undergone several substantial refinements and expansions; the latest gnomAD database release encompasses exome sequence data from 123 136 individuals and whole-genome sequence data from 15 496 individuals, representing a data set of 277 264 alleles. Although presence of a disease-associated allele does not preclude pathogenicity, a significant number is shown to be present at a frequency incompatible with causation of penetrant disease and have been downgraded to either VUS or even likely benign in ClinVar. A sizeable number of purported disease-causing variants for FHC (25.2%; 322 out of 1280 reported in the HGMD), DCM (29.2%; 222/759), and ARVC (34.6%, 167/483) are found in the ExAC data set. 35 The frequency of FHC is 1 in 500 people (representing an estimated allele frequency of 0.001) 36 ; however recent reports have recommended using much more stringent allele frequency cutoffs of 0.0001 35 and 0.00004 20 to account for disease penetrance and maximum allelic contribution (based on the prevalence of the most common causal allele observed in FHC populations). Therefore, any FHC-associated variant with an allele frequency above the cutoff of 0.0001 in ExAC or gnomAD is not likely to be pathogenic.
We discovered LMNA p.R644C, SCN5A p.F2004 and V1951L, KCNH2 p.S347S, and CAV3 p.C72W in our cohorts that were found in reference data sets with allele frequencies higher than the expected disease allele frequencies. 37, 38 Furthermore, patients harboring either LMNA p.R644C, 39 KCNH2 p.P347S or SCN5A p.V1951L, p.F2004L or p.F2006A variants 40, 41 present with negligible disease phenotype; therefore, these variants were excluded as potentially causal. Another previously published variant found in our cohort, CACNA1C p.G37R, 42 has also been discovered at relatively high frequencies (1.4% in ExAC) and is considered likely benign. Nunn et al 31 recently reported the G37R variant in an SUD proband with phenotype-positive relatives who, at the time of publication, were awaiting genotyping and whose outcome may influence its future classification. The recent and ongoing changes to putative disease-associated variants highlight the issue that variant interpretation requires a cautious approach and is subject to frequent updates. We recommend that clinicians using molecular genetic analysis to guide patient treatment periodically reexamine their genetic findings as many purportedly disease-associated variants are frequently being reassessed. We have included a list of recently downgraded variants we discovered in our cohorts in the Table  II in the Data Supplement. ClinVar is the only database, to our knowledge, that allows updated annotations and will likely continue to expand its contribution to variant interpretation with increased submissions in future.
Limitations
We had limited access to clinical information on our cases, and as yet, no access to family data. Without cosegregation analysis, it is unknown whether the identified variants are inherited or sporadic, impeding interpretation of some variants. In most cases, ethnicity and ancestry were unknown, which prevented variant cross-checking with appropriate ethnicity-matched reference databases. We have not yet undertaken or completed functional analyses for novel variants, which limits our current interpretation of these findings.
Some genes (eg, CAMK2D and CAMK2G) had low coverage despite several refinements to experimental protocols. Therefore, heterozygous variants may have been missed because of poor representation in our captures.
Conclusions
We investigated a large cohort of autopsy-negative child SUD cases using molecular autopsy to assist in finding a diagnosis. We found a high proportion of cardiomyopathy-associated variants, which suggests that both cardiomyopathy and ion channelopathy genes be included in NGS panels investigating SUDY. Although this study was successful in discovering potentially causal variants in SUDY cases, we strongly urge that variant interpretation requires a cautious and stringent approach. The study also clearly indicates the importance of studying genes expressed primarily in early developmental stages (eg, TNNI1) and are usually not included in molecular autopsies.
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